Cerner finds a treasure in data mining - Portland Business Journal:

borislavamcoc.blogspot.com
The North Kansas City-based health care information technology company, known mostly for the health-record softwarse sold to hospitals and clinics, is leveragin g the billions of anonymous patient records it has at its disposap as marketable information to pharmaceutical companies and Cerner said the data operation is a big reasob revenue for its LifeSciences Group has increased by roughly 20 percent during each of the past five Mark Hoffman, the company’s life sciences solutions vice predicted that annual growth will be greatee still in the future. “This is just the beginnin g for us in thelife sciences,” he Included in Cerner’s data warehouse are 1.
2 billion lab results. It also has smalle numbers of medication orders andotherf data. The company collects the informationthrough data-sharinhg agreements with roughly 125 of its softwaree clients. By some estimates, it can take as long as 17 yearszand $1.2 billion to develop a single drug. Cerner’se data-mining capabilities can quicken that proces and save money for drug companies by helping the companies establisjh a study protocol that maximizesw the number of eligible candidates fora “We believe that can actually eventually reduc the cost of drug development,” Hoffman Cerner would not name its pharmaceutical Pharmaceutical companies and clinical researchers pay for Cernere data for other reasons, said Scott director of the ’s Officed of Therapeutics Discovery and Development.
He said Cerner’s data-mining capabilityy can point scientists to potential new uses forexisting drugs. For Weir said, Cerner’s database mightf suggest that a drug used to treat cardiovasculadr disease could be helpful in treatingcancer patients. Researchers then coulfd run a clinical trial to testthe idea. The data is usefupl to drug companies for much the same Weir said, including helping them identify and correct side effects from drugs. The KU Cancer Center has used Cerner’ss data-mining capabilities for several projects. “They uncover information we wouldnever discover,” Weir said. “It’s invaluable.
” He said Cerner stands to benefitg financially, as well, from collaborations with researchersa that can lead to intellectual propertt that produces licensing fees and Cerner also can work with researcherss suchas Dr. Stephen Spielberg, director of the Center for Personalized Medicine and Therapeutic Innovationat . Spielberg seeks a $3.9 milliojn grant from the for a study of how the center can bettee capture data in pediatric canceer studies usingCerner